POST Online Media Lite Edition



 

Roche extends offer deadline for Spark Therapeutics again

Christian Fernsby |
Roche has again extended the deadline for its tender offer for Spark Therapeutics saying U.S. and British anti-trust authorities needed more time to review the deal.

Article continues below



Topics: ROCHE    SPARK THERAPEUTICS   

The offer, which was originally due to expire on Nov. 25, has now been extended to December 10. All terms and conditions of the offer remain the same, Roche said. So far 14.8% of the shares were tendered.

Roche has put back the deadline several times since it announced the $4.3 billion offer to buy the gene therapy company in February.


What to read next

Roche enters strategic collaboration with Foundation Medicine
Autodesk announces $100 million 3D investment fund
New Zealand rejects Huawei's first 5G bid citing national security risk